This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion: Sirna

Shares of Rockwell Medical Technologies (RMTI - Get Report) were up 24% after the hemodialysis products maker said second-quarter sales increased 77.8% over last year. Net income in the second quarter was $85,456, or 1 cent a share. Separately, the company said the European Patent and Trademark Office will issue a patent for its proprietary iron delivery product. Rockwell was up 77 cents to $3.97.

China Medical Technologies (CMED) was gaining 15% on its first day of trading after pricing an initial public offering at $15 a share. Shares of the China-based medical devices company were up $2.30 to $17.30.

Coley Pharmaceutical Group (COLY) rose nearly 18% after selling shares in an initial public offering at $16 each. The biopharmaceutical company's stock was rising $2.83 to $18.83.

KV Pharmaceutical (KV.A) was climbing 6.5% after the company's revenue for the first quarter rose 29% to $85.5 million. After a writeoff of 62 cents a share for a product acquisition, the company lost 45 cents a share. Excluding this writeoff, adjusted earnings for the first quarter would have been $8.5 million, or 16 cents a share, topping estimates by 3 cents. The specialty pharmaceutical company rose $1.06 to $17.15.

Curative Health Services (CURE) dropped 28% after the company posted revenue of $71.6 million and a loss was $4.8 million, or 37 cents a share, for the second quarter. Before items, the company would have lost 31 cents. Curative shares lost 96 cents to $2.52.

CuraGen (CRGN) sank nearly 14% after the biopharmaceutical company priced a public offering of 4 million shares at $5.50 each. The proceeds of the offering will be about $21 million. Shares of CuraGen were down 82 cents to $5.24.

Sirna Therapeutics (RNAI) fell 8% after reporting a loss of $5.9 million, or 14 cents a share, for the second quarter. Revenue for the second quarter was $1.5 million. Shares of the clinical-stage biotechnology company were losing 34 cents to $3.76.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CURE $23.28 0.00%
RMTI $6.50 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs